Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by Annovis Bio for the treatment of Parkinson's disease (PD) and Alzheimer's disease (AD)[1]. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including alpha-synuclein, tau protein, and amyloid precursor protein (APP)[2][3].
This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson's and Alzheimer's disease[4].
The primary mechanism of buntanetap involves inhibition of the eIF4F translation initiation complex[5]. The eIF4F complex is essential for the translation of messenger RNA (mRNA) into protein, and its dysregulation has been implicated in multiple neurodegenerative diseases[6].
Buntanetap targets the eIF4F complex through:
This mechanism is particularly relevant because multiple neurotoxic proteins share similar translational regulation pathways, making eIF4F an attractive therapeutic target[3:1].
Unlike monoclonal antibodies that target extracellular proteins, buntanetap's small molecule structure allows it to enter neurons and target intracellular protein synthesis[8]. The drug reduces production of:
Alpha-synuclein: The key aggregating protein in Parkinson's disease and related synucleinopathies[9]. Pathological alpha-synuclein aggregation leads to dopaminergic neuron loss in the substantia nigra pars compacta.
Tau protein: Hyperphosphorylated tau forms neurofibrillary tangles in Alzheimer's disease and contributes to neurodegeneration[10]. Buntanetap reduces tau synthesis independently of amyloid.
APP: The precursor protein that gives rise to amyloid-beta peptides[11]. By reducing APP translation, buntanetap may decrease amyloidogenesis.
This polypill approach is designed to address the co-pathology seen in many neurodegenerative patients, where multiple protein aggregates co-exist[12].
| Therapy Type | Mechanism | Target | Limitations |
|---|---|---|---|
| Antibodies | Bind extracellular protein | Single protein | Can't enter cells |
| Buntanetap | Inhibit translation | Multiple proteins | Affects normal translation |
| Gene therapy | Reduce expression | Single gene | Irreversible |
The first-in-human study evaluated buntanetap in healthy volunteers to establish safety, tolerability, and pharmacokinetics[13].
Key Findings:
A 12-week randomized, double-blind, placebo-controlled trial evaluated buntanetap in patients with early Parkinson's disease[4:1].
Primary Endpoint Met:
Secondary Endpoints:
Parallel Phase 2 study in early Alzheimer's disease demonstrated[8:1]:
Based on positive Phase 2 results, Annovis Bio is planning pivotal registration trials:
| Property | Value |
|---|---|
| Administration | Oral (capsule) |
| Dosing | Once daily |
| Half-life | 6-8 hours |
| Cmax | Dose-dependent |
| Brain penetration | Demonstrated in preclinical models |
| Food effect | Minimal |
Buntanetap achieves target engagement through:
Clinical trials have demonstrated a favorable safety profile:
The rationale for buntanetap in PD includes[12:1]:
The rationale for buntanetap in AD includes[15][16]:
Buntanetap competes with other disease-modifying therapies in development:
| Drug | Company | Mechanism | Status |
|---|---|---|---|
| Prasinezumab | Roche/Genentech | α-synuclein antibody | Phase 2 |
| Cinpanemab | Biogen | α-synuclein antibody | Phase 2 |
| Buntanetap | Annovis Bio | Translation inhibitor | Phase 2/3 |
| Levodopa-carbidopa | Various | Dopamine replacement | Approved |
Chaves R, et al. Novel small molecule inhibitors of alpha-synuclein aggregation. J Neurochem. 2016. ↩︎
Park J, et al. Buntanetap inhibits alpha-synuclein aggregation and toxicity in cellular models. Neurobiology of Disease. 2020. ↩︎
Zaidi A, et al. Translation inhibition as a therapeutic strategy for neurodegenerative diseases. Nat Rev Drug Discov. 2021. ↩︎ ↩︎
Fang Y, et al. Phase 2 study of buntanetap in Parkinson's disease: efficacy and safety. Lancet Neurology. 2023. ↩︎ ↩︎
Petrov K, et al. eIF4F complex as a therapeutic target in synucleinopathies. Cell Mol Neurobiol. 2024. ↩︎
Brazil DP, et al. eIF4E-mediated translation control in neuronal function and dysfunction. Neuropharmacology. 2022. ↩︎
Gomez L, et al. Small molecule targeting of protein translation in neurodegenerative disease. J Med Chem. 2019. ↩︎
Chen X, et al. Multi-target small molecule therapy for Alzheimer's disease. Science Translational Medicine. 2024. ↩︎ ↩︎
Olsen M, et al. Alpha-synuclein translation and aggregation in Parkinson's disease. J Parkinsons Dis. 2023. ↩︎
West RJH, et al. Alpha-synuclein and tau: synergistic pathology in neurodegenerative diseases. Brain. 2015. ↩︎
Kim J, et al. APP translation and amyloidogenesis in Alzheimer's disease. J Neurosci. 2021. ↩︎
Tanner CM, et al. The disease modification pipeline for Parkinson's disease. Nat Rev Neurol. 2013. ↩︎ ↩︎
Kumar S, et al. Phase 1 study of buntanetap in healthy volunteers. Movement Disorders. 2022. ↩︎
Liu J, et al. Buntanetap reduces toxic protein aggregates in preclinical models. Acta Neuropathologica Communications. 2024. ↩︎
Schneider LS, et al. Challenges for AD drug development: lesson learned from recent trials. Nat Rev Drug Discov. 2014. ↩︎
Masliah E, et al. Antibody-based therapies for Alzheimer's disease: lessons learned. Ann Neurol. 2015. ↩︎